Immune-Targeted Antipsoriatic Drug Development Services

Characterized by rapid keratinocyte proliferation and immune cell infiltration, psoriasis requires targeted therapies that can modulate the immune response while minimizing side effects. At Ace Therapeutics, we specialize in providing comprehensive drug development services that focus on modulating immune responses to address the pathogenesis of psoriasis.

Overview of Immune-Targeted Antipsoriatic Drugs

Immune-targeted therapies aim to correct the aberrant immune responses that underpin psoriasis. Key cytokines and immune pathways, such as interleukin-17 (IL-17), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-α), play a central role in the inflammatory cascades observed in psoriatic lesions and are integral targets in current therapeutic approaches.

• Biologics: Monoclonal antibodies targeting cytokines such as IL-17 and IL-23 have shown significant efficacy in clinical settings. Agents like secukinumab (anti-IL-17A) effectively reduce inflammation and keratinocyte proliferation.
• Small Molecule Inhibitors: JAK inhibitors disrupt intracellular signaling related to multiple cytokines, offering a broad therapeutic effect. Deucravacitinib, a selective Tyk2 inhibitor, exemplifies this approach, demonstrating superior efficacy in clinical trials.
• Emerging Therapeutics: New classes of drugs, such as S1P receptor modulators, are being explored for their ability to regulate immune responses and lymphocyte migration, providing additional options for psoriasis management.

Fig. 1 Epithelial immune microenvironment in psoriasis. (Li L, et al., 2024)

Comprehensive Immune-Targeted Antipsoriatic Drug Development Services

At Ace Therapeutics, we offer comprehensive services that cover the entire spectrum of drug development for immune-targeted antipsoriatic therapies.

MyD88 Inhibitor Development Services

• Target Validation and Mechanistic Studies: We use genetic models and pharmacological approaches to validate MyD88 as a therapeutic target and elucidate its role in psoriasis models.
• In Vitro Assays: Using cytokine release and cell viability & proliferation assays to evaluate the effects of MyD88 inhibitors on psoriasis-related inflammation and cell activity.
• In Vivo Efficacy Studies: By utilizing psoriasis models to conduct pharmacokinetic and pharmacodynamic studies, we provide essential data to support clients in the development of psoriasis therapies.

T-Cell Activation Inhibitor Development Services

• Target Identification: We assist clients in identifying key targets involved in T-cell activation, enabling the design of tailored inhibitors.
• Compound Screening: Utilizing high-throughput screening methods to evaluate potential inhibitors against T-cell activation, allowing for rapid identification of promising candidates.
• Mechanism of Action Studies: Comprehensive analysis of how inhibitors affect T-cell signaling and function, providing insights necessary for optimizing drug candidates.

Optimization of Immune Modulation Strategies

• In Vitro Immune Assays: We conduct assays to assess the effects of drug candidates on various immune cell populations, including T cells, dendritic cells, and macrophages, helping in understanding how treatments can affect immune responses.
• Cytokine Profiling: Measuring cytokine levels in response to treatments to evaluate the modulatory effects on inflammatory pathways.
• Combination Therapy Evaluations: Assessing potential synergies between different immunomodulatory agents to enhance therapeutic efficacy.

Preclinical Efficacy Testing

• In Vivo Models: We utilize animal models that mimic human psoriasis to evaluate the efficacy of drug candidates, such as imiquimod-induced psoriasis and genetically modified models that exhibit psoriatic lesions.
• Cytokine Release Assays: Measuring the release of key cytokines from immune cells in response to drug candidates, providing insights into their anti-inflammatory effects.
• Histopathological Analysis: Comprehensive evaluation of skin tissue from animal studies to assess the impact of treatments on psoriatic lesions, including inflammation and keratinocyte activity.

Ace Therapeutics is poised to support your immune-targeted antipsoriatic therapy development needs with our extensive expertise and resources. Contact us today to discuss how we can assist you in advancing your research projects.